As a global leader in medical technology, services and solutions, Medtronic improves the health and lives of millions of people each year.We believe our deep clinical, therapeutic and economic expertise can help address the complex challenges—such as rising costs, aging populations, and the burden of chronic disease—faced by families and healthcare systems today. But, we can’t do it alone. That’s why we’re committed to partnering in new ways and developing powerful solutions that deliver better patient outcomes.
Founded in 1949 as a medical repair company, we're now among the world's largest medical technology, services and solutions companies, employing more than 85,000 people worldwide, serving physicians, hospitals and patients in more than 160 countries. Join us in our commitment to take healthcare Further, Together. Learn more at Medtronic.com.
Nordmark is specialized in the production of active pharmaceutical ingredients and drug products of both biological and biotechnological origin. We have successfully positioned ourselves in this niche market of the pharmaceutical industry as an internationally leading company/producer of pancreatic enzyme preparations. With more than 90 years of experience and excellent delivery capacities we are a trustworthy partner for patients and partners worldwide. It is our utmost effort to be close to patients’ requirements as well as working in close cooperation with experts. Focussed on their needs we provide helps us provide comprehensive therapy information to patients as well as scientific support to physicians.
Company Summary: OncoSil Medical is a global medical device company focused on Interventional Oncology. Company Description: OncoSil Medical’s mission is to improve the outcomes for people living with cancer by utilising the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in combination with chemotherapy. OncoSil™ is our brachytherapy device. Its targeted approach enables healthcare professionals to deliver a greater radiation dose directly into the tumour compared to external beam radiotherapy, while sparing surrounding critical organs. 1 We believe in our technology and its ability to have a truly positive impact in Oncology. Reference: 1. Skowronek J. J Contemp Brachytherapy 2017; 9: 581-589.